176 related articles for article (PubMed ID: 32561906)
1. HIV, progestins, genital epithelial barrier function, and the burden of objectivity†.
Vicetti Miguel RD; Quispe Calla NE; Cherpes TL
Biol Reprod; 2020 Aug; 103(2):318-322. PubMed ID: 32561906
[TBL] [Abstract][Full Text] [Related]
2. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
Hapgood JP
AIDS Res Hum Retroviruses; 2020 May; 36(5):357-366. PubMed ID: 31797677
[TBL] [Abstract][Full Text] [Related]
3. Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?
Polis CB; Achilles SL; Hel Z; Hapgood JP
Contraception; 2018 Mar; 97(3):191-197. PubMed ID: 29242082
[No Abstract] [Full Text] [Related]
4. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
[TBL] [Abstract][Full Text] [Related]
5. Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.
Hapgood JP; Kaushic C; Hel Z
Endocr Rev; 2018 Feb; 39(1):36-78. PubMed ID: 29309550
[TBL] [Abstract][Full Text] [Related]
6. Progestin-only contraception: injectables and implants.
Jacobstein R; Polis CB
Best Pract Res Clin Obstet Gynaecol; 2014 Aug; 28(6):795-806. PubMed ID: 24996766
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: HIV Shedding in the Female Genital Tract of Women on ART and Progestin Contraception: Extended Follow-up Results of a Randomized Clinical Trial.
Kourtis AP; Wiener J; Hurst S; Nelson JAE; Cottrell ML; Corbett A; Chinula L; Msika A; Haddad LB; Tang JH
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):163-165. PubMed ID: 31095006
[TBL] [Abstract][Full Text] [Related]
8. Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
Birse KD; Romas LM; Guthrie BL; Nilsson P; Bosire R; Kiarie J; Farquhar C; Broliden K; Burgener AD
J Infect Dis; 2017 Feb; 215(4):590-598. PubMed ID: 28011908
[TBL] [Abstract][Full Text] [Related]
9. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
Chinula L; Nelson JAE; Wiener J; Tang JH; Hurst S; Tegha G; Msika A; Ellington S; Hosseinipour MC; Mataya R; Haddad LB; Kourtis AP
Contraception; 2018 Sep; 98(3):193-198. PubMed ID: 29746813
[TBL] [Abstract][Full Text] [Related]
10. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
11. Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi.
Zia Y; Tang JH; Chinula L; Tegha G; Stanczyk FZ; Kourtis AP
Contraception; 2019 Nov; 100(5):402-405. PubMed ID: 31374188
[TBL] [Abstract][Full Text] [Related]
12. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
Haddad LB; Tang JH; Davis NL; Kourtis AP; Chinula L; Msika A; Tegha G; Hosseinipour MC; Nelson JAE; Hobbs MM; Gajer P; Ravel J; De Paris K
mSphere; 2023 Feb; 8(1):e0058522. PubMed ID: 36622252
[TBL] [Abstract][Full Text] [Related]
13. Progestin-based contraception regimens modulate expression of putative HIV risk factors in the vaginal epithelium of pig-tailed Macaques.
Bosinger SE; Tharp GK; Patel NB; Zhao C; Payne TL; Dietz Ostergaard S; Butler K; Ellis S; Johnson RL; Kersh EN; McNicholl JM; Vishwanathan SA
Am J Reprod Immunol; 2018 Oct; 80(4):e13029. PubMed ID: 30076667
[TBL] [Abstract][Full Text] [Related]
14. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
15. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.
Polis CB; Phillips SJ; Curtis KM; Westreich DJ; Steyn PS; Raymond E; Hannaford P; Turner AN
Contraception; 2014 Oct; 90(4):360-90. PubMed ID: 25183264
[TBL] [Abstract][Full Text] [Related]
16. Cervical and systemic concentrations of long acting hormonal contraceptive (LARC) progestins depend on delivery method: Implications for the study of HIV transmission.
Buckner LR; Drobnis EZ; Augustine MS; Rogers LK; Akers J; Mott PD; Hope TJ; Quayle AJ; Schust DJ
PLoS One; 2019; 14(5):e0214152. PubMed ID: 31095572
[TBL] [Abstract][Full Text] [Related]
17. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.
Byrne EH; Anahtar MN; Cohen KE; Moodley A; Padavattan N; Ismail N; Bowman BA; Olson GS; Mabhula A; Leslie A; Ndung'u T; Walker BD; Ghebremichael MS; Dong KL; Kwon DS
Lancet Infect Dis; 2016 Apr; 16(4):441-8. PubMed ID: 26723758
[TBL] [Abstract][Full Text] [Related]
18. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
[TBL] [Abstract][Full Text] [Related]
19. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
20. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
